公开(公告)号：EP3265127A1

公开(公告)日：2018-01-10

申请号：EP16759295.5

申请日：2016-02-25

申请人： Corcept Therapeutics, Inc.

发明人： MORAITIS, Andreas G. ,  BELANOFF, Joseph K.

IPC分类号： A61K45/06 ,  C07D413/06

CPC分类号： A61K31/567 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/513 ,  A61K38/08 ,  A61K38/12 ,  A61K45/06 ,  A61K51/083 ,  A61P3/10 ,  A61P35/00 ,  A61K2300/00

摘要： Methods, compositions, and pharmaceutical formulations are provided for treatment of ACTH secreting tumors.

公开(公告)号：EP3405101A1

公开(公告)日：2018-11-28

申请号：EP17741860.5

申请日：2017-01-18

申请人： Corcept Therapeutics, Inc.

发明人： MORAITIS, Andreas G.

IPC分类号： A61B5/00 ,  G01N33/74

CPC分类号： G01N33/743 ,  A61B5/4227 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/723 ,  G01N2800/04 ,  G16H50/30

摘要： Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.

公开(公告)号：EP3297728A1

公开(公告)日：2018-03-28

申请号：EP16797242.1

申请日：2016-05-18

申请人： Corcept Therapeutics, Inc.

发明人： BELANOFF, Joseph K. ,  HUNT, Hazel ,  UNITT, John Francis ,  MORAITIS, Andreas G.

IPC分类号： A61P5/00 ,  A61P5/46 ,  A61K45/06

CPC分类号： C12Q1/6883 ,  A61K31/4745 ,  A61K31/567 ,  A61K31/573 ,  A61K45/06 ,  A61P5/46 ,  C12Q1/533 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y502/01008 ,  G01N33/573 ,  G01N33/743 ,  G01N2333/723 ,  G01N2333/99 ,  G01N2800/04 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.

公开(公告)号：EP3277281A1

公开(公告)日：2018-02-07

申请号：EP16774094.3

申请日：2016-03-30

申请人： Corcept Therapeutics, Inc.

发明人： MORAITIS, Andreas G. ,  COHAN, Pejman ,  BELANOFF, Joseph K.

IPC分类号： A61K31/496 ,  A61K31/5377 ,  A61K31/5375

CPC分类号： A61K31/567 ,  A61K31/437 ,  A61K31/473 ,  A61K31/513 ,  A61K31/575

摘要： This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 μg/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.

公开(公告)号：EP3592358A1

公开(公告)日：2020-01-15

申请号：EP18763240.1

申请日：2018-03-08

申请人： Corcept Therapeutics, Inc.

发明人： MORAITIS, Andreas G.

IPC分类号： A61K31/57 ,  A61K51/08

公开(公告)号：EP3335043A1

公开(公告)日：2018-06-20

申请号：EP16836011.3

申请日：2016-08-12

申请人： Corcept Therapeutics, Inc.

发明人： MORAITIS, Andreas G.

IPC分类号： G01N33/50 ,  A61K31/575 ,  C07D217/08

CPC分类号： G01N33/74 ,  A61K31/4745 ,  A61K31/567 ,  A61K31/573 ,  G01N2333/695 ,  G01N2800/048

摘要： This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.